ASCO24: J&J Reports Four Patient Deaths in Early-Stage Prostate Cancer Trial

Four patients died in Johnson & Johnson’s Phase I study for its investigational targeted radiopharmaceutical candidate JNJ-6420 in metastatic castration-resistant prostate cancer, according to a Thursday readout released ahead of next week’s American Society of Clinical Oncology annual meeting.